Search

Your search keyword '"Allergan PLC -- Product development"' showing total 12 results
Start Over Descriptor "Allergan PLC -- Product development" Journal m2 presswire
12 results on '"Allergan PLC -- Product development"'

1. Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch Health

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, GSK PLC -- Product development, Nestlé S.A. -- Product development, Medical research, Medicine, Experimental, Patient compliance, Atopic dermatitis, Roflumilast -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-January 7, 2025-: Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch [...]

Published
2025

2. ABSSSI Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials by DelveInsight | Merck & Co. Inc., Endo Pharma, Nabriva Therapeutics, Basilea Pharma, Cipher Pharma, Paratek

Subjects
Merck & Company Inc. -- Product development, Paratek Pharmaceuticals Inc. -- Product development, Allergan PLC -- Product development, Business -- Research, Skin -- Care and treatment -- Health aspects, Infection -- Health aspects, Clinical trials -- Health aspects, Dalbavancin -- Health aspects, Antibiotics -- Product development, Pharmaceutical industry -- Product development, Business, Business, international, Zevtera (Medication) -- Product development -- Health aspects
Abstract

M2 PRESSWIRE-July 3, 2024-: ABSSSI Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials by DelveInsight | Merck & Co. Inc., Endo Pharma, Nabriva Therapeutics, Basilea Pharma, Cipher Pharma, [...]

Published
2024

3. Benign Prostatic Hyperplasia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Boehringer Ingelheim, Merck & Co. Inc., Allergan PLC

Subjects
Astellas Pharma Inc. -- Product development, Merck & Company Inc. -- Product development, Allergan PLC -- Product development, Boehringer Ingelheim GmbH -- Product development, Nymox Pharmaceutical Corp. -- Product development, Therapeutics Inc. -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Prostate -- Hypertrophy, Drugs -- Product development, Clinical trials -- Reports, Instrument industry -- Product development, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-May 6, 2024-: Benign Prostatic Hyperplasia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Boehringer Ingelheim, Merck & Co. Inc., Allergan [...]

Published
2024

4. Postoperative Pain Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Novartis AG, Allergan plc, Teva

Subjects
Allergan PLC -- Product development, Novartis AG -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Business -- Research, Clinical trials -- Reports, Pain -- Care and treatment, Analgesics -- Product development, Pain, Postoperative -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-November 9, 2023-: Postoperative Pain Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Novartis AG, Allergan plc, Teva [...]

Published
2023

5. Cystic Fibrosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Genentech Inc., Novartis AG, Gilead Sciences Inc., Vertex Pharma

Subjects
Allergan PLC -- Product development, Genentech Inc. -- Product development, Vertex Pharmaceuticals Inc. -- Product development, AbbVie Inc. -- Product development, Gilead Sciences Inc. -- Product development, Novartis AG -- Product development, Biological products industry -- Product development, Business -- Research, Medical research -- Reports, Medicine, Experimental -- Reports, Cystic fibrosis -- Reports, Biotechnology industry -- Product development, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 6, 2023-: Cystic Fibrosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Genentech Inc., Novartis AG, Gilead Sciences Inc., Vertex [...]

Published
2023

6. Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L' Oreal SA & Huons Global Co Ltd

Subjects
Allergan PLC -- Product development, L'Oreal S.A. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Cosmetics industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-January 28, 2020-: Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L' Oreal SA & Huons Global Co Ltd (C)1994-2020 M2 COMMUNICATIONS RDATE:28012020 [...]

Published
2020

7. Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, Eisai Company Ltd. -- Product development, Clinical trials, Anti-Alzheimer's disease agents -- Product development, Pharmaceutical industry -- Product development, Alzheimer's disease, Business, Business, international
Abstract

M2 PRESSWIRE-January 27, 2020-: Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation (C)1994-2020 M2 COMMUNICATIONS RDATE:27012020 The 'Alzheimer's [...]

Published
2020

8. Allergan's ubrogepant meets in Phase III for acute migraine

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine, Business, Business, international
Abstract

M2 PRESSWIRE-February 7, 2018-: Allergan's ubrogepant meets in Phase III for acute migraine (C)1994-2018 M2 COMMUNICATIONS RDATE:06022018 Allergan plc (NYSE:AGN) said ubrogepant (MK-1602) met the co-primary endpoints in the Phase [...]

Published
2018

9. Essential Tremor Global Clinical Trials Review, H2, 2015 - Key Players are Allergan Plc, Sage Therapeutics & Pfizer Inc

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Tremor, Business, Business, international
Abstract

M2 PRESSWIRE-March 8, 2016-: Essential Tremor Global Clinical Trials Review, H2, 2015 - Key Players are Allergan Plc, Sage Therapeutics & Pfizer Inc. (C)1994-2016 M2 COMMUNICATIONS RDATE:08032016 Dublin - Research [...]

Published
2016

10. Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2015 - Key Players are GlaxoSmithKline Plc, Novartis AG & Allergan Plc

Subjects
Allergan PLC -- Product development, Novartis AG -- Product development, GlaxoSmithKline PLC -- Product development, Clinical trials, Irritable bowel syndrome, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-March 7, 2016-: Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2015 - Key Players are GlaxoSmithKline Plc, Novartis AG & Allergan Plc (C)1994-2016 M2 COMMUNICATIONS RDATE:07032016 Dublin - [...]

Published
2016

11. Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015 - Key Vendors: Allergan Plc, ANI Pharmaceuticals, Inc. & Palatin Technologies, Inc

Subjects
Allergan PLC -- Product development, ANI Pharmaceuticals Inc. -- Product development, Palatin Technologies Inc. -- Product development, Clinical trials, Sexual disorders, Pharmaceutical industry -- Product development, Biological products industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-January 18, 2016-: Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015 - Key Vendors: Allergan Plc, ANI Pharmaceuticals, Inc. & Palatin Technologies, Inc. (C)1994-2016 M2 COMMUNICATIONS RDATE:18012016 Dublin [...]

Published
2016

12. Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, AstraZeneca PLC -- Product development, Bacterial infections -- Care and treatment -- Health aspects, Urinary tract infections -- Care and treatment -- Health aspects, Antibiotics -- Product development -- Health aspects, Pharmaceutical industry -- Product development -- Health aspects, Business, Business, international
Abstract

M2 PRESSWIRE-September 2, 2015-: Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections (C)1994-2015 M2 COMMUNICATIONS RDATE:02092015 AstraZeneca today announced positive topline results from [...]

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results